The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Efficacy of D-RVD vs RVD in patients with newly diagnosed t(11;14) multiple myeloma
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, provides the highlights from a study looking at a real-world comparison of patients with t(11;14) multiple myeloma (MM) treated with either lenalidomide, bortezomib, and dexamethasone (RVD) or daratumumab+RVD (D-RVD) induction therapy and assessing response and outcomes. The study aimed to address whether adding daratumumab to RVD confers a treatment benefit in patients with newly-diagnosed MM. In this cohort, the addition of daratumumab improved the very good partial response (VGPR) rate and progression-free survival (PFS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Incyte, BMS, Sanofi
